MPM in iOmx Therapeutics' €40m series-A

MPM co-led the round alongside Sofinnova Partners, with further backing from Wellington Partners and Merck Ventures. As part of the deal, Sofinnova partner Henrijette Richter joined the company's board of directors.

The proceeds of the financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.

Company
Founded in 2016 and based in Munich, iOmx is a biopharmaceutical company developing cancer therapeutics based on immune checkpoint targets. By systematically screening human tumour cells, the company has identified a number of new targets and analysed their mode of action.

People
Sofinnova Partners – Henrijette Richter (partner).
iOmx – Sebastian Meier-Ewert (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Sofinnova Partners
• Wellington Partners
• Venture